Literature DB >> 2635517

An analysis of ocular counter-rolling measured with search coils.

S Takemori1, M Tanaka, H Moriyama.   

Abstract

Ocular counter-rolling (OCR) was studied by using a scleral search coil magnetic system in normal subjects and in pathological cases. Normal ocular counter-rolling was 2.7 degrees-7 degrees when the head was tilted 10 to 30 degrees. In most cases of benign paroxysmal positional vertigo, the OCR to the ipsilateral side was reduced, while that to the contralateral side was normal or only slightly reduced. Soon after unilateral labyrinthectomy, the OCR to the ipsilateral side was reduced or was 0, whereas OCR to the contralateral side was normal or slightly reduced. Some 3-5 years after the operation, however, the OCR seemed to depend on the compensation achieved. In cases of acoustic neurinoma, OCR to both sides was reduced, that to the ipsilateral side being more strongly impaired than the OCR to the contralateral side.

Entities:  

Mesh:

Year:  1989        PMID: 2635517     DOI: 10.3109/00016488909139060

Source DB:  PubMed          Journal:  Acta Otolaryngol Suppl        ISSN: 0365-5237


  4 in total

1.  Human ocular torsion during parabolic flights: an analysis with scleral search coil.

Authors:  B S Cheung; K Money; I Howard; N Kirienko; W Johnson; J Lackner; P Dizio; J Evanoff
Journal:  Exp Brain Res       Date:  1992       Impact factor: 1.972

2.  Effects of spaceflight on ocular counterrolling and the spatial orientation of the vestibular system.

Authors:  M Dai; L McGarvie; I Kozlovskaya; T Raphan; B Cohen
Journal:  Exp Brain Res       Date:  1994       Impact factor: 1.972

3.  Human ocular torsional position before and after unilateral vestibular neurectomy.

Authors:  I S Curthoys; M J Dai; G M Halmagyi
Journal:  Exp Brain Res       Date:  1991       Impact factor: 1.972

4.  Ocular Counter Rolling in Astronauts After Short- and Long-Duration Spaceflight.

Authors:  Millard F Reschke; Scott J Wood; Gilles Clément
Journal:  Sci Rep       Date:  2018-05-17       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.